Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 733958
                    [Title] => Roche lung cancer drug receives FDA approval
                    [Summary] => 
Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
                    [DatePublished] => 2011-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626491
                    [Title] => Extending the life of people with lung cancer
                    [Summary] => 
MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung cancer.
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

        )

)

ERLOTINIB

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 733958
                    [Title] => Roche lung cancer drug receives FDA approval
                    [Summary] => 
Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
                    [DatePublished] => 2011-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626491
                    [Title] => Extending the life of people with lung cancer
                    [Summary] => 
MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung cancer.
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

        )

)

abtest

Roche lung cancer drug receives FDA approval

October 6, 2011 - 12:00am

Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small...

Science and Environment

Roche bares study results on lung cancer medicine

May 26, 2011 - 12:00am

Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small...

Science and Environment

Early success of Roche drug vs lung cancer cited

February 3, 2011 - 12:00am

SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.

Science and Environment

Roche gets license for EGFR lung cancer assay

November 25, 2010 - 12:00am

Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.

Science and Environment

Extending the life of people with lung cancer

November 4, 2010 - 12:00am

MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung c...

Science and Environment

Roche's lung cancer drug receives positive opinion in Europe

By LPM | April 23, 2010 - 12:00am

Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell...

Cebu News